Innovation in diagnostics

A real-time view of processes within the body

Liquid biopsy offers a breakthrough solution for the early detection and dynamic monitoring of cancer. Without invasive intervention, reliably and with targeted manner.

Liquid biopsy

During conventional tissue biopsy, a single localized sample from the tumor is examined, which only partially reflects the tumor's complete genetic composition. By contrast, liquid biopsy is based on the analysis of tumor-derived DNA (ctDNA) circulating in the blood, which may potentially carry genetic alterations from all tumor tissue present in the body, thus providing a more comprehensive view of the disease.

1. Priskin K. et al., "BC-Monitor: Towards a Routinely Accessible Circulating Tumor DNA-Based Tool for Real-Time Monitoring Breast Cancer Progression and Treatment Effectiveness", Cancers (Basel), vol. 13, no. 14, p. 3489, Jul. 2021, doi: 10.3390/cancers13143489.

Innovation in diagnostics

A real-time view of processes within the body

Liquid biopsy offers a breakthrough solution for the early detection and dynamic monitoring of cancer. Without invasive intervention, reliably and with targeted manner.

Liquid biopsy

During conventional tissue biopsy, a single localized sample from the tumor is examined, which only partially reflects the tumor's complete genetic composition. By contrast, liquid biopsy is based on the analysis of tumor-derived DNA (ctDNA) circulating in the blood, which may potentially carry genetic alterations from all tumor tissue present in the body, thus providing a more comprehensive view of the disease.

The transformation of oncology

Challenges and solutions in cancer diagnostics

One of the greatest challenges in cancer diagnostics today is to obtain a real-time and accurate view of processes taking place in the body. Biological changes begin much earlier than they become physically visible.

Liquid Biopsy

This method is a modern diagnostic technology based on the analysis of cell-free nucleic acids and tumor-derived DNA and RNA fragments that can be extracted from various body fluids, such as saliva, blood or urine.

Tumors release tiny genetic signals into the bloodstream even at very early stages. The more actively a tumor grows, the more of these molecular signals appear. Changes in their quantity and genetic patterns can be monitored in real time. By detecting small amounts of tumor-derived DNA present in the blood, liquid biopsy provides an opportunity for the early identification of molecular changes, including recurrence.

Thanks to modern sequencing technologies, this test can now be performed with high sensitivity and a short turnaround time, making it applicable in clinical practice.

Liquid biopsy is therefore not only a new testing method, but a shift in perspective that enables continuous molecular-level monitoring of the tumor. BC-Monitor implements this approach in clinical practice and has been specifically optimized for breast cancer follow-up.

BC-Monitor

Clinical application of BC-Monitor

BC-Monitor has been specifically optimized for breast cancer follow-up. Its clinical suitability for monitoring breast cancer was validated in a prospective clinical study.

0-0

Months of advantage

On average, ctDNA monitoring indicated disease progression this much earlier than conventional methods.

Patients enrolled

It was tested in a prospective cohort study across different therapeutic settings.

Plasma samples

Were processed during the study, enabling continuous monitoring.

Clinical validation

In approximately two-thirds of patients, the tumor tissue genetic test forming the basis of BC-Monitor detected a somatic mutation that later became trackable. The results support that the method is suitable for molecular-level tumor monitoring in a significant proportion of patients.¹

ctDNA monitoring

What this can mean in everyday practice

BC-Monitor is built on a targeted gene panel that examines the most common clinically relevant genetic alterations in breast cancer (12 genes, 38 target regions). Its use provides direct, tangible benefits for patients and treating physicians alike.

Early molecular indication of treatment effectiveness

Real-time monitoring of the tumor's molecular changes, including the emergence of new resistant clones

Continuous blood-based monitoring with minimal burden for the patient.

Early molecular-level indication of recurrence (relapse) before clinical manifestation

FAQ

Frequently Asked Questions

We have collected the most common questions about BC-Monitor.

BC-Monitor does not replace imaging tests; it complements them. CT, MRI or PET scans show the size and location of the tumor. BC-Monitor, by contrast, monitors the molecular status of the tumor. It is important to emphasize that liquid biopsy can often detect tumor progression months earlier than conventional imaging procedures.

Contact

If you would like to discuss BC-Monitor in more detail, please complete this form and we will contact you.

A real-time view of processes within the body

Liquid biopsy

A real-time view of processes within the body

Liquid biopsy

The transformation of oncology

Challenges and solutions in cancer diagnostics

Liquid Biopsy

BC-Monitor

Clinical application of BC-Monitor

Months of advantage

Patients enrolled

Plasma samples

Clinical validation

ctDNA monitoring

What this can mean in everyday practice

Early molecular indication of treatment effectiveness

Real-time monitoring of the tumor's molecular changes, including the emergence of new resistant clones

Continuous blood-based monitoring with minimal burden for the patient.

Early molecular-level indication of recurrence (relapse) before clinical manifestation

Compared with traditional, snapshot-like histological examinations, BC-Monitor's liquid biopsy-based molecular monitoring may provide complementary, dynamic information about the tumor's current status.

FAQ

Frequently Asked Questions

Does BC-Monitor replace imaging tests?

Exactly which genes does BC-Monitor examine?

Can BC-Monitor be used instead of tumor markers (e.g. CA15-3, CEA)?

What does it mean if no alteration is detected during the test?

Can tumor DNA always be detected from blood?

Does current treatment affect the test result?

How often should the test be repeated?

When is sampling recommended?

Can the test also be performed if cancer is suspected?

Contact

BC-Monitor

European Life Technologies

BC-Monitor

European Life Technologies

BC-Monitor

European Life Technologies

BC-Monitor

European Life Technologies

The transformation of oncology

Challenges and solutions in cancer diagnostics

Liquid Biopsy

BC-Monitor

Clinical application of BC-Monitor

Months of advantage

Patients enrolled

Plasma samples

Clinical validation

ctDNA monitoring

What this can mean in everyday practice

Early molecular indication of treatment effectiveness

Real-time monitoring of the tumor's molecular changes, including the emergence of new resistant clones

Continuous blood-based monitoring with minimal burden for the patient.

Early molecular-level indication of recurrence (relapse) before clinical manifestation

Compared with traditional, snapshot-like histological examinations, BC-Monitor's liquid biopsy-based molecular monitoring may provide complementary, dynamic information about the tumor's current status.

FAQ

Frequently Asked Questions

Does BC-Monitor replace imaging tests?

Exactly which genes does BC-Monitor examine?

Can BC-Monitor be used instead of tumor markers (e.g. CA15-3, CEA)?

What does it mean if no alteration is detected during the test?

Can tumor DNA always be detected from blood?

Does current treatment affect the test result?

How often should the test be repeated?

When is sampling recommended?

Can the test also be performed if cancer is suspected?

Contact

BC-Monitor

European Life Technologies

BC-Monitor

European Life Technologies

BC-Monitor

European Life Technologies

BC-Monitor

European Life Technologies